NSE filing, NSE: LALPATHLAB. Summary written from the filing by ALFA Finder's alert engine.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹1,911.70
- Market cap
- ₹32,088 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 59.2×Sector 52.3×
- Promoter holding
- 52.93%-0.26% QoQ
- FII holding
- 18.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs updated its 4 November 2026 board meeting notice to add a possible second interim dividend. The meeting will also approve unaudited quarterly results.
Dr. Lal Pathlabs Acquisition Worth ₹30.3 Cr
Dr. Lal PathLabs subscribed to WOS PUPL equity to fund PUPL's buyout of remaining 30% in CentraPath Labs for ₹30.3 Crore. CentraPath becomes a wholly owned subsidiary.
- Value
- ₹30.30 Cr
Dr. Lal Pathlabs Other Announcement
Dr. Lal PathLabs submitted the quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, received from its RTA.
Dr. Lal Pathlabs Legal & Regulatory
Dr. Lal PathLabs disclosed an ITAT tax appeal against a favorable order for Rs.32.66 Crore ESOP expense relief (AY 2022-23). The company expects no material financial impact.
- Value
- ₹32.66 Cr
Dr. Lal Pathlabs Other Announcement
Dr. Lal PathLabs reported PIT disclosures for trades by designated persons and its Employee Welfare Trust, totaling approximately ₹0.83 Crore. These involved ESOP allotments and market sales.
- Value
- ₹0.09 Cr
Dr. Lal Pathlabs Acquisition Worth ₹38 Cr
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
- Value
- ₹38.00 Cr
Other results update announcements
All →Aatmaj Healthcare Results Update
Aatmaj Healthcare reported H1 FY27 revenue of Rs. 16.96 crore and EBITDA of Rs. 2.04 crore. The company targets 80% revenue growth for FY27.
RPG Life Sciences Results Update
RPG Life Sciences reported Q2 FY27 revenue of ₹211.6 crore, growing 16.5%, and adjusted EBITDA of ₹50.1 crore. The API business integration continues to progress.
Praruh Technologies Results Update
Praruh Technologies reported strong H1 FY27 growth, with revenue rising 378% YoY to ₹84.06 Crore and PAT increasing 733% to ₹8.18 Crore.
CARE Ratings Results Update
CARE Ratings reported strong Q2 and H1 FY27 operating income and profit growth. The board also declared an interim dividend of Rs 10 per share.
EPACK Durables Results Update
EPACK Durable reported record first-half revenue and strong Q2 FY27 growth. The board also approved exiting its EPAVO joint venture stake.
3i Infotech Results Update
3i Infotech reported Q2FY27 revenue of Rs.182.0 crore, up 4.1% year-on-year. Quarterly PAT stood at Rs.6.7 crore and 25 new client wins were added.